Browse by ▼

Eli Lilly & Co.

  • Is This Healthcare Company a Strong Investment?

    By Lior Cohen - June 13, 2013 | Tickers: LLY, JNJ, PG

    The slowdown in stock market has also adversely affected leading healthcare companies’ stocks. But many still think investing in healthcare giants such as Johnson & Johnson (NYSE: JNJ) is the right move. Let’s take a closer look at this company and break down its main strong points, opportunities, and risks.

    J&J continues to grow

    Johnson & Johnson has done well in the first quarter of 2013: The company’s revenues more »

  • Is Pfizer a Buy?

    By Robert Ciura - June 11, 2013 | Tickers: BMY, LLY, PFE

    The biggest pharmaceutical companies in the United States are in an enviable position. They sell products that are literally a matter of life and death. People who take medication will pay for it no matter what, and will often cut back on many other necessary expenses if need be.

    As a result it should be no surprise that some of the market’s best performers last year came from the more »

  • Billionaire Stanley Druckenmiller's Big 5

    By Marshall Hargrave - June 8, 2013 | Tickers: DHI, LLY, GOOG, LEN, PFE

    Billionaire Stanley Druckenmiller founded his Duquesne Capital hedge fund in 1981. It now has some $10 billion in assets under management. Previously, Druckenmiller managed money for George Soros from 1988 to 2000, and was the lead portfolio manager for Soros' famous Quantum Fund. Outlined below are Druckenmiller's top five stocks going into the second quarter, let's check them out (see Druckenmiller's selloffs).
     
    Housing bets
     
    Druckenmiller's top more »

  • Big Things Are Happening at This Pharmaceutical Company

    By Timothy Green - June 7, 2013 | Tickers: LLY, MRK, PFE

    Pharmaceutical company Pfizer (NYSE: PFE) has been doing some interesting things lately. The company has been shedding its non-pharmaceutical assets in order to focus on its core business which carries high profit margins. In April 2012, Pfizer sold its infant nutrition business to Nestle, and this February, the company spun off its animal health business Zoetis.

    Pfizer's stock has fallen more than 10% from its high in April, pushing more »

  • Billionaire Jim Simons' Buy Ups

    By Marshall Hargrave - June 7, 2013 | Tickers: BMY, LLY, GOOG, IBM

    Billionaire Jim Simons founded Renaissance Technologies ("RenTech"), his private investment firm, in 1982. Simons is renowned for his Medallion Fund, which made Simons one of the richest people in the world. Basically, the Medallion Fund employs high-frequency trading and exploits inefficiencies in the stock market. The expenses are high for the fund; it charges a 5% fixed fee, while also charging a 44% performance fee. Currently the fund’s investors more »

  • Sarissa's Stake in VIVUS Points to Renewed Interest in the Company

    By Mike Thiessen - June 6, 2013 | Tickers: LLY, GSK, VVUS

    Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS (NASDAQ: VVUS). Although it had been widely anticipated by keen-eyed market observers, this event nevertheless highlighted the renewed interest in VIVUS' long-term prospects.

    Like many small biotech firms that focus on developing and marketing experimental or advanced drugs, VIVUS has had a volatile run over the past few years. After several quarters more »

  • Pfizer's Big Chance

    By Terry Chrisomalis - June 6, 2013 | Tickers: LLY, GSK, PFE, VVUS

    When we think of big pharma companies, the company we think about constantly is Pfizer (NYSE: PFE), especially as the company recently announced it will start selling Viagra online. This is a bold move, and I think that Pfizer has the financial backing to make it work. 

    There are other problems that Pfizer has to deal with here, like counterfeit pills from online pharmacies. Pfizer knows that this problem will more »

  • Profiting from Diabetes Expenses

    By Nathaniel Matherson - June 5, 2013 | Tickers: LLY, MDT

    In the past I have found success investing in companies that provide exposure to growing themes. I have invested in popular themes such as healthcare, craft beers, and global tobacco, to name just a few. The benefit of theme investing is that even if the company you select for investment has difficultly, the struggles are often not represented in the performance of the security as investors bid up the entire more »

  • Synta Pharmaceuticals: A Promising Biotech Stock for 2013

    By Ted Mayer - June 4, 2013 | Tickers: LLY, SNY, SNTA

    Biotechnology stocks offer investors some of the highest potential for returns of any industry.  However, these stocks also come with incredible risk that can cause share prices to rise and fall because of binary events.  This is especially true for small-cap biotech stocks, particularly in the cancer space.  One biotech stock that appears to be a future winner is Synta Pharmaceuticals (NASDAQ: SNTA).

    Synta Pharmaceuticals is a development stage biotechnology more »

  • 3 FDA Stories You Missed This Week

    By Brandy Betz - June 3, 2013 | Tickers: CELG, LLY, GSK, MRK

    Editor's Note: The initial article refers to Abraxane's prostate cancer trials. That is incorrect, Abraxane has priority review for pancreatic cancer. This version has been corrected and Motley Fool apologizes for the error.

    The Food and Drug Administration stays busy with approvals, recommendations, and reviews. Three stories straddled the holiday weekend and carried major pipeline news for the companies involved.   

    Merck’s (NYSE: MRK) insomnia drug won a more »

  • The Diabetes Drug War

    By Robinson Roacho - June 2, 2013 | Tickers: BMY, LLY, SNY

    Technological advances have allowed for people to have more longevity. Drug companies research and develop medicines to prevent, control and cure diseases. Diabetes is a condition in which the levels of glucose increase above normal levels. This condition can be fatal if the glucose levels are not controlled. Eli Lilly (NYSE: LLY) and Sanofi (NYSE: SNY) are two major players that I believe will bring capital appreciation to their investors more »

  • 4 Big Drug Companies With Big Juicy Yields

    By David Dierking - May 22, 2013 | Tickers: LLY, MRK, PFE, TEVA

    Drug companies have been revenue generating machines for long. They’re in the enviable position of being able to profit from the aging of America by providing a product that will be in continuous demand. While those revenue streams can hit some peaks and troughs due to things like drug patent expiration (something that Pfizer (NYSE: PFE) will be dealing with shortly with its big name drug Lipitor), the big more »

  • Do Major Drug Manufacturers Have Room to Grow?

    By Chris Hodge - May 21, 2013 | Tickers: AZN, LLY, ZTS

    Major drug manufacturers are literally a market sector unto themselves. With valuations that frequently soar into the $50 billion level and beyond, these companies have already grown to incredible proportions. But can they grow further still, or is the best they can do to keep going along a steady path?

    Never underestimate a dark horse

    AstraZeneca (NYSE: AZN) is a Swedish and British company, which automatically puts its epicenter into more »

  • Diagnosing Alzheimer's First

    By Seth Robey - May 17, 2013 | Tickers: BAX, LLY, JNJ, PFE

    Alzheimer's is a debilitating neurodegenerative disorder affecting approximately 5 million Americans, yet its causes are remarkably enigmatic.  Nonetheless, pharma and biotech companies continually throw money at potential blockbusters that lack innovative scientific forethought and inevitably fail to meet primary endpoints in clinical trials.  Their gamble is over a piece of the $203 billion pie that the Alzheimer's Association estimates as a 2013 cost of care (rising to an more »

  • This Sector Is No Bargain

    By Robert Ciura - May 15, 2013 | Tickers: BMY, LLY, PFE

    Many stocks within the pharmaceutical industry have rallied significantly over the past few years and now sit at multi-year highs. It’s not hard to understand why: in today’s investing environment of historically low interest rates, bank products like certificates of deposit pay little to no interest. The 10-Year Treasury Bond still yields less than 2%, so high-quality equities like these stocks that provide yields in excess of 3 more »

  • These Stocks Are Still Solid Long-Term Picks

    By Jarrod Bailey - May 15, 2013 | Tickers: LLY, MRK, PFE

    Confirmation bias – one of the psychological traps investors can be most prone to falling victim to. What happens to us as investors when we are influenced by this bias is we essentially discount all information that counters our established view point. If we are bullish on a particular stock, then confirmation bias will mean we will tend to overemphasize the importance of bullish news relative to bearish news. Confirmation bias more »

  • 6 Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part I

    By Meena Krishnamsetty - May 10, 2013 | Tickers: BMY, LLY, JNJ

    The healthcare sector has been known for paying dependable dividends and producing strong total returns over time. Among the major pharmaceutical companies, there are a few that stand out as most financially sound, as reflected by their CDS spreads below those of the U.S. Treasuries.

    Why use CDS spreads?

    A credit default swap is essentially like a form of insurance, that two parties can swap between one another for more »

  • London-Based Hedgie Focusing On Big Pharma

    By Meena Krishnamsetty - May 10, 2013 | Tickers: LLY, JNJ, MRK, MSFT, PFE

    By law, institutional investors with over $100 million in investment discretion in Section 13(f), are required within 45 days after the end of a calendar quarter to file the 13F form with the SEC. The 13F form discloses all of the US-listed publicly traded holdings in a fund's equity portfolio. One of the most recent filings belongs to London-based RWC Asset Management LLP. Reading on will take you more »

  • Is All Well With These 4 Pharmaceutical Powerhouses?

    By Nauman Aly - April 30, 2013 | Tickers: LLY, GSK, MRK

    In the world of big pharmaceuticals, investors have come to realize that dividend income is traditionally steady, while the share price may or may not move a great deal other than when a new breakthrough drug has been approved. As is the case, share price can also oftentimes struggle. Those big pharmas that can keep promising new products on the forefront - while at the same time keeping their dividend payout more »

  • Are Dividend Yields the Cure for Pharma Investors' Woes?

    By Nauman Aly - April 30, 2013 | Tickers: BMY, LLY, GSK

    As the market continues to climb, investors are beginning to see thinning dividend yields on many of their big pharma shares. But by sticking with quality - and with companies that are keeping their product pipelines full with new drugs - one can certainly find the key to not just share growth but also a nice steady income along the way.

    Keeping yields healthy

    One of the higher yielding big pharmaceutical companies more »

  • Page 1 of 8